The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
July 16th 2025
Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Real-World Users of Triple Therapy for Asthma in the US
This retrospective cohort study evaluated baseline demographics, clinical characteristics, and treatment patterns of US patients with asthma who newly initiated single- or multiple-inhaler triple therapy.
Read More
Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer
February 9th 2024Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.
Watch
House Republicans voted to ban quality-adjusted life years (QALYs) from being used as a drug pricing metric in federal health programs; insurance executives disapproved of newly proposed 2025 Medicare Advantage (MA) rates; patients with long COVID enrolled in an online exercise program said their health improved more than people who received standard care.
Read More
Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes, but Questions on Optimal Use Remain
February 8th 2024Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.
Watch
Possible Increase in Prevalence of Alzheimer Disease Found in Patients With Myasthenia Gravis
February 6th 2024Investigators observed an increase in the prevalence of Alzheimer disease in patients with diagnosed myasthenia gravis (MG), which indicates that MG is an independent risk factor for AD.
Read More
Ever-Smokers With COPD Have a Greater Risk of Developing ADHD, Study Says
February 6th 2024No causal association with psychiatric disorders was observed in patients with chronic obstructive pulmonary disease (COPD) without a smoking history, while ever-smokers with COPD had a greater risk of developing attention-deficit/hyperactivity disorder (ADHD).
Read More
Study Highlights Relationship Between Alcohol Use, Socioeconomic Status, and IHD Mortality Risk
February 6th 2024Light-to-moderate alcohol consumption seemed to provide greater protection against ischemic heart disease (IHD) mortality for individuals with higher socioeconomic status (SES) compared with those with lower SES, likely due to gaps in access to necessary care.
Read More
Targeted Therapy Associated With Lower SPM Risk Among Treated Patients With CLL
February 6th 2024Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.
Read More
Pre-, Postinfusion Protocol Recommendations for Delandistrogene Moxeparvovec Use in DMD
February 5th 2024The gene therapy delandistrogene moxeparvovec-rokl, also known as Elevidys (Sarepta Therapeutics) is indicated to treat Duchenne muscular dystrophy (DMD) in ambulatory patients aged 4 to 5 years, and Sarepta recently filed supplemental data with the FDA seeking to expand the labeled indication.
Read More
Dr Ann LaCasce Looks to the Year Ahead in the Lymphoma Treatment Landscape
February 2nd 2024Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses potential shifts in the lymphoma space in the year ahead.
Watch
CD137+ Tumor Infiltrating Lymphocytes Correlate With OS in Ovarian Cancer, Study Finds
February 2nd 2024In patients with high-grade ovarian cancer, an increased proportion of CD3+ CD137+ tumor infiltrating lymphocytes (TILs) correlated with favorable overall survival outcomes. However, proportions of CD3+ or CD3+ CD8+ TILs did not show significant associations with OS.
Read More